




INOVATYON



Phase III international, randomised study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with relapsed ovarian cancer progressing within 6–12 months of last platinum

- Sponsor: MaNGO group
Istituto di Ricerche Farmacologiche Mario Negri – Milano
- PI: Nicoletta Colombo, IEO Milano
- Final No. of patients: **618** / 117 enrolling sites
- January 2014 First Patient In
- **September 2017 accrual close-out**
- Abstract ASCO 2018 for Compliance, Safety, Response
- Second Interim Analysis with 2/3 of deaths ~Oct 2018
- Final Analysis ~ July–August 2020

